President & CEO Conte and CSO Chaturvedi provide updates on the five clinical efforts: 3 POC investigator-initiated trials and two company Phase II studies in rare disease indications (MVID) and (SBS-IF) on a conference call to be held on December 18 at 11 am hosted by Ladenburg Thalmann. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health granted Orphan Drug designation for crofelemer for diarrhea
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health announces results of crofelemer for CTD in breast cancer patients
- Jaguar Health to present data on crofelemer for CTD in breast cancer patients
- Jaguar Health announces publication of article on Canalevia-CA1